KYMR Stock Price, Kymera Therapeutics, . Quote, Chart

Market Summary

USD38.43-0.01

Delayedas of 08 May 2024, 11:51 am

-0.03%

KYMR Alerts

Losses in recent quarter

KYMR Stock Price

View Fullscreen

KYMR RSI Chart

KYMR Valuation

Market Cap

2.4B

Price/Earnings (Trailing)

-15.26

Price/Sales (Trailing)

29.7

Price/Free Cashflow

-17.3

KYMR Price/Sales (Trailing)

KYMR Profitability

Return on Equity

-21.74%

Return on Assets

-17.8%

Free Cashflow Yield

-5.78%

KYMR Fundamentals

KYMR Revenue

Revenue (TTM)

79.4M

Rev. Growth (Yr)

8.67%

Rev. Growth (Qtr)

-78.52%

KYMR Earnings

Earnings (TTM)

-154.6M

Earnings Growth (Yr)

-18.64%

Earnings Growth (Qtr)

-237.95%

Breaking Down KYMR Revenue

52 Week Range

12.9438.70

(Low)(High)

Last 7 days

14.4%

Last 30 days

5.7%

Last 90 days

13.8%

Trailing 12 Months

38.6%

How does KYMR drawdown profile look like?

KYMR Financial Health

Current Ratio

9.57

KYMR Investor Care

Shares Dilution (1Y)

10.94%

Diluted EPS (TTM)

-2.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	79.4M	0	0	0
2023	46.7M	51.7M	46.8M	78.6M
2022	63.8M	56.7M	46.0M	46.8M
2021	49.3M	64.5M	70.3M	72.8M
2020	10.7M	18.5M	26.3M	34.0M
2019	0	0	0	2.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Kymera Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	booth bruce	sold	-2,903,340	40.4567	-71,764	-
Mar 14, 2024	booth bruce	sold	-2,229,930	39.9779	-55,779	-
Mar 13, 2024	atlas venture fund x, l.p.	sold	-1,020,420	42.2273	-24,165	-
Mar 13, 2024	booth bruce	sold	-5,880,420	42.2277	-139,255	-
Mar 13, 2024	atlas venture fund x, l.p.	sold	-4,859,990	42.2278	-115,090	-
Mar 12, 2024	atlas venture fund x, l.p.	sold	-1,186,740	41.9773	-28,271	-
Mar 12, 2024	booth bruce	sold	-6,838,810	41.977	-162,918	-
Mar 12, 2024	atlas venture fund x, l.p.	sold	-5,652,070	41.977	-134,647	-
Mar 11, 2024	atlas venture fund x, l.p.	sold	-1,812,590	42.8487	-42,302	-
Mar 11, 2024	atlas venture fund x, l.p.	sold	-380,562	42.8465	-8,882	-

Which funds bought or sold KYMR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Atlas Venture Life Science Advisors, LLC	reduced	-8.21	67,018,600	216,170,000	19.95%
May 06, 2024	Jefferies Financial Group Inc.	reduced	-3.77	264,374	611,040	-%
May 06, 2024	Candriam S.C.A.	reduced	-4.37	4,456,880	13,197,700	0.08%
May 06, 2024	Parallel Advisors, LLC	unchanged	-	118	322	-%
May 06, 2024	TEACHER RETIREMENT SYSTEM OF TEXAS	added	8.1	149,000	361,000	-%
May 06, 2024	SG Americas Securities, LLC	reduced	-78.7	-314,000	159,000	-%
May 06, 2024	Integrated Advisors Network LLC	new	-	249,964	249,964	0.01%
May 03, 2024	Smartleaf Asset Management LLC	new	-	616	616	-%
May 03, 2024	SIGNATUREFD, LLC	unchanged	-	870	2,372	-%
May 03, 2024	Riggs Asset Managment Co. Inc.	new	-	282	282	-%

Are Funds Buying or Selling KYMR?

Are funds buying KYMR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own KYMR

No. of Funds

KYMR Alerts

Losses in recent quarter

Unveiling Kymera Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 01, 2024	baker bros. advisors lp	9.8%	5,997,706	SC 13D
Feb 14, 2024	avoro capital advisors llc	6.8%	3,775,000	SC 13G/A
Feb 13, 2024	vanguard group inc	6.73%	3,997,564	SC 13G/A
Feb 12, 2024	price t rowe associates inc /md/	10.1%	5,999,256	SC 13G/A
Feb 12, 2024	price t rowe associates inc /md/	9.6%	5,340,414	SC 13G/A
Feb 09, 2024	atlas venture fund x, l.p.	8.4%	4,968,114	SC 13G/A
Feb 08, 2024	wellington management group llp	8.68%	4,815,558	SC 13G/A
Jan 29, 2024	blackrock inc.	6.4%	3,566,611	SC 13G/A
Jan 23, 2024	state street corp	3.41%	1,894,279	SC 13G/A
Jan 10, 2024	baker bros. advisors lp	10.8%	5,995,928	SC 13G/A

Recent SEC filings of Kymera Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 01, 2024	3	Insider Trading
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	SC 13D	13D - Major Acquisition
Mar 15, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Kymera Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.4B	6.8B	17.66%	-8.12%	-7.77	6.77	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.5B	2.0B	0.45%	-26.53%	-58.76	9.74	75.20%	68.82%
BMRN	15.7B	2.5B	-4.99%	-13.89%	76.35	6.35	13.74%	186.89%
INCY	12.2B	3.8B	-1.56%	-17.34%	16.38	3.24	8.58%	129.81%
MID-CAP
APLS	5.3B	524.1M	-21.34%	-51.87%	-12.77	10.17	394.93%	39.61%
BBIO	5.2B	107.9M	-1.17%	105.40%	-9.51	48.09	54.84%	-28.31%
AXSM	3.7B	251.0M	6.53%	-0.98%	-12.33	14.56	73.58%	-86.73%
ARWR	3.1B	240.7M	-3.03%	-38.20%	-10.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-4.16%	-19.91%	-46.38	3.91	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-0.20%	-12.84%	24.99	4.48	85.90%	-14.05%
NVAX	645.2M	983.7M	4.30%	-38.12%	-1.18	0.66	-50.36%	17.16%
CRBP	424.2M	881.7K	-0.70%	291.81%	-12.56	481.06	-77.61%	33.36%
INO	259.6M	4.9M	-5.85%	11.55%	-1.92	53.35	-54.97%	51.71%
IBIO	7.1M	2.1M	-3.32%	88.89%	-0.26	2.14	-13.45%	66.37%

Kymera Therapeutics, Inc. News

Latest updates

Kymera Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	-78.5%	10,287	47,885	4,728	16,513	9,466	16,139	9,551	11,514	9,622	15,275	20,336	18,519	18,702	12,785	14,533	3,288	3,428	2,189	950
Operating Expenses	1.4%	68,118	67,197	62,237	59,896	54,792	54,770	54,433	52,324	46,555	49,269	48,973	43,249	31,871	25,567	22,616	17,480	14,675	-	12,811
S&GA Expenses	-100.0%	-	14,227	14,120	14,129	12,565	11,636	10,556	11,031	10,611	11,740	10,667	8,029	5,909	5,175	6,838	3,661	2,559	-	1,501
R&D Expenses	-7.8%	48,819	52,970	48,117	45,767	42,227	43,134	43,877	41,293	35,944	37,529	38,306	35,220	25,962	20,392	15,778	13,819	12,116	-	11,310
Interest Expenses	4.3%	49.00	47.00	37.00	26.00	52.00	55.00	38.00	40.00	46.00	52.00	52.00	30.00	24.00	27.00	23.00	31.00	34.00	-	-
Net Income	-238.0%	-48,557	-14,368	-52,867	-38,799	-40,928	-34,865	-43,002	-40,257	-36,684	-33,900	-28,582	-24,660	-13,075	-12,685	-7,986	-13,989	-10,932	-	-11,420
Net Income Margin	-4.1%	-1.95*	-1.87*	-3.57*	-3.05*	-3.41*	-3.31*	-3.35*	-2.46*	-1.94*	-1.38*	-1.12*	-0.90*	-	-	-	-	-	-	-
Free Cashflow	-1212.7%	-46,993	-3,580	-39,725	-46,024	-47,977	-39,909	-35,515	-39,720	-40,777	-38,853	-37,566	-31,137	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	50.8%	868	576	552	582	614	603	638	523	563	606	642	434	465	487	507	117
Current Assets	32.6%	537	405	376	385	412	419	494	403	431	451	544	365	341	302	297	93.00
Cash Equivalents	-15.0%	94.00	110	81.00	52.00	50.00	68.00	156	77.00	34.00	48.00	157	85.00	53.00	31.00	55.00	76.00
Net PPE	2.5%	49.00	48.00	36.00	27.00	17.00	13.00	13.00	13.00	12.00	12.00	12.00	12.00	11.00	11.00	11.00	4.00
Liabilities	-13.1%	157	181	157	147	152	113	126	125	134	146	159	176	189	203	213	82.00
Current Liabilities	-34.5%	56.00	86.00	63.00	55.00	62.00	71.00	91.00	88.00	88.00	93.00	94.00	109	110	111	107	35.00
Shareholder's Equity	80.1%	711	395	396	435	462	490	513	398	429	460	483	258	275	284	295	-
Retained Earnings	-9.1%	-579	-530	-516	-463	-424	-383	-348	-305	-265	-228	-195	-166	-141	-128	-116	-76.46
Additional Paid-In Capital	39.5%	1,292	926	914	903	890	879	868	708	698	689	678	425	417	413	411	2.00
Shares Outstanding	5.1%	61.00	58.00	55.00	55.00	55.00	54.00	55.00	52.00	52.00	48.00	47.00	45.00	-	-	-	-
Float	-	-	-	-	1,013	-	-	-	792	-	-	-	1,688	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-592.1%	-39,591	8,045	-31,647	-35,256	-43,968	-39,536	-34,269	-38,985	-40,295	-38,352	-37,260	-30,511	-22,823	-20,068	131,667	-11,412	-12,057	-	-
Share Based Compensation	9.8%	11,968	10,898	11,655	11,180	9,385	8,909	9,076	9,622	7,873	8,678	7,396	5,726	3,172	1,827	2,328	664	371	-	-
Cashflow From Investing	-1844.4%	-330,607	18,952	60,511	35,839	24,584	-49,666	-37,481	81,803	25,863	-68,019	-136,862	60,723	44,323	-3,990	-334,321	-46,874	-37,403	-	-
Cashflow From Financing	18191.4%	353,756	1,934	-206	1,305	1,159	1,953	150,497	364	185	2,054	246,039	1,592	595	270	196,275	-403	93,120	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

KYMR Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration Revenue—from related parties	$ 10,287	$ 9,466
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	us-gaap:RelatedPartyMember	us-gaap:RelatedPartyMember
Operating expenses:
Research and development	$ 48,819	$ 42,227
General and administrative	14,374	12,565
Impairment of long-lived assets	4,925	0
Total operating expenses	68,118	54,792
Loss from operations	(57,831)	(45,326)
Other income (expense):
Interest and other Income	9,343	4,453
Interest and other expense	(69)	(55)
Total other income:	9,274	4,398
Net loss	(48,557)	(40,928)
Other comprehensive loss:
Unrealized gain (loss) on marketable securities	(1,225)	1,911
Total comprehensive loss	(49,782)	(39,017)
Net loss	$ (48,557)	$ (40,928)
Net loss per share, basic and diluted	$ (0.69)	$ (0.7)
Net loss per share, basic and diluted	$ (0.69)	$ (0.7)
Weighted average common shares outstanding, basic and diluted	70,770,320	58,187,038
Weighted average common shares outstanding, basic and diluted	70,770,320	58,187,038

KYMR Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 93,510	$ 109,966
Marketable securities (Note 4)	427,034	264,915
Accounts receivable	0	15,000
Contract assets	2,030	3,762
Prepaid expenses and other current assets	14,679	11,674
Total current assets	537,253	405,317
Marketable securities, non-current (Note 4)	224,390	61,434
Property and equipment, net (Note 6)	49,336	48,134
Right-of-use assets, operating leases	49,329	52,945
Other non-current assets	2,118	2,118
Restricted cash	5,825	5,811
Total assets	868,251	575,759
Current liabilities:
Accounts payable	6,812	7,075
Accrued expenses (Note 8)	15,997	33,864
Deferred revenue	22,613	37,883
Operating lease liabilities	8,757	5,068
Finance lease liabilities	1,133	1,277
Other current liabilities	824	524
Total current liabilities	56,136	85,691
Non-current liabilities
Deferred revenue, net of current portion	23,781	16,768
Operating lease liabilities, net of current portion	75,975	77,028
Finance lease liabilities, net of current portion	1,156	1,301
Total liabilities	157,048	180,788
Stockholders’ equity:
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023, 61,353,146 and 55,585,305 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	6	6
Additional paid-in capital	1,292,283	926,269
Accumulated deficit	(579,309)	(530,752)
Accumulated other comprehensive loss	(1,777)	(552)
Total stockholders’ equity	711,203	394,971
Total liabilities and stockholders’ equity	$ 868,251	$ 575,759

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Nello Mainolfi M.D., Ph.D.
WEBSITE	kymeratx.com
INDUSTRY	Biotechnology
EMPLOYEES	181

Kymera Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Kymera Therapeutics, Inc.? What does KYMR stand for in stocks?

KYMR is the stock ticker symbol of Kymera Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Kymera Therapeutics, Inc. (KYMR)?

As of Tue May 07 2024, market cap of Kymera Therapeutics, Inc. is 2.36 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KYMR stock?

You can check KYMR's fair value in chart for subscribers.

What is the fair value of KYMR stock?

You can check KYMR's fair value in chart for subscribers. The fair value of Kymera Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Kymera Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for KYMR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Kymera Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether KYMR is over valued or under valued. Whether Kymera Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Kymera Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KYMR.

What is Kymera Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, KYMR's PE ratio (Price to Earnings) is -15.26 and Price to Sales (PS) ratio is 29.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KYMR PE ratio will change depending on the future growth rate expectations of investors.